LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Home・Akcijų sąrašas・MannKind Corp

MannKind Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

3.3 1.54

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.13

Max

3.34

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-671K -17M
Pardavimai	-22M 90M
P/E Sektoriaus vid.	140.5 49.701
Pelnas, tenkantis vienai akcijai	-0.02
Pelno marža	-18.431
Darbuotojai	591
EBITDA	5.9M 3.4M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+127.79% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	56M 924M
Ankstesnė atidarymo kaina	1.76
Ankstesnė uždarymo kaina	3.3

Naujienos nuotaikos

By Acuity

60%

40%

292 / 345 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

4.079 / 4.323 Palaikymas ir pasipriešinimas

MannKind Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-21 22:48; UTC

Įsigijimai, susijungimai, perėmimai

Conduent to Sell Public Transit Business to Modaxo for $164 Million

2026-05-21 16:49; UTC

Uždarbis

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

2026-05-21 16:26; UTC

Pagrindinės rinkos jėgos

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

2026-05-21 23:51; UTC

Rinkos pokalbiai

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

2026-05-21 23:37; UTC

Uždarbis

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

2026-05-21 23:37; UTC

Uždarbis

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

2026-05-21 23:37; UTC

Uždarbis

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

2026-05-21 23:34; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

2026-05-21 23:30; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-21 23:30; UTC

Rinkos pokalbiai

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

2026-05-21 22:33; UTC

Įsigijimai, susijungimai, perėmimai

Conduent to Sell Public Transit Business to Modaxo for $164M

2026-05-21 21:53; UTC

Uždarbis

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

2026-05-21 21:02; UTC

Uždarbis

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

2026-05-21 20:55; UTC

Uždarbis

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

2026-05-21 20:30; UTC

Karštos akcijos

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

2026-05-21 20:20; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-21 20:20; UTC

Rinkos pokalbiai

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

2026-05-21 20:20; UTC

Uždarbis

Webull 1Q Adj EPS 3c >BULL

2026-05-21 20:20; UTC

Uždarbis

Webull 1Q Rev $159.9M >BULL

2026-05-21 20:18; UTC

Rinkos pokalbiai

Mexico's Inflation Seen Easing in Early May -- Market Talk

2026-05-21 20:18; UTC

Uždarbis

Webull 1Q Loss/Shr 4c

2026-05-21 19:43; UTC

Rinkos pokalbiai

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

2026-05-21 19:33; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

2026-05-21 18:58; UTC

Uždarbis

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

2026-05-21 18:15; UTC

Rinkos pokalbiai

Gold Higher For Second Consecutive Day -- Market Talk

2026-05-21 17:40; UTC

Rinkos pokalbiai

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

2026-05-21 17:04; UTC

Rinkos pokalbiai

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

2026-05-21 17:01; UTC

Uždarbis

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

2026-05-21 16:20; UTC

Rinkos pokalbiai

Uždarbis

Stellantis Targets Distant but Constructive -- Market Talk

2026-05-21 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

MannKind Corp Prognozė

Kainos tikslas

By TipRanks

127.79% į viršų

12 mėnesių prognozė

Vidutinis 7.54 USD 127.79%

Aukščiausias 10 USD

Žemiausias 4.75 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines MannKind Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių MannKind Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

4.079 / 4.323Palaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

All events are bearish.

Bearish events outweigh bullish events.

Rinkos nuotaikos

By Acuity

292 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.